Security Snapshot

ISHARES TR - ISHARES BIOTECH (IBB) Institutional Ownership

CUSIP: 464287556

13F Institutional Holders and Ownership History from Q1 2014 to Q2 2026

Latest Period

Q1 2026

Institutions Reporting

915

Shares (Excl. Options)

41,771,933

Price

$168.85

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0.01%
Share change
+452,472
Value change
+$61,131,133
Number of holders
915
Issuer context Names, identifiers, and filing context for this profile. 1 identity field
SEC-reported price per share
$190.19
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • IBB - ISHARES TR - ISHARES BIOTECH is tracked under CUSIP 464287556.
  • 915 institutions reported positions in Q1 2026.
  • Schedule 13D/13G significant owner rows are not currently available.

Change

  • Holder count moved from 915 to 18 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from $7,034,321,876 to $17,698,265.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 915 institutions filings for Q1 2026.

Open SEC evidence

Security key

464287556

Latest holder period

Q1 2026

13F holders

915

13D/G owners

0

CIK / CUSIP context first

As of 31 Mar 2026, 915 institutional investors reported holding 41,771,933 shares of ISHARES TR - ISHARES BIOTECH (IBB).

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
50
Latest
Q1 2026
Rows shown
1-25 of 50
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q2 93,055 $17,698,265 -$2,492,229 $190.19 18
2026 Q1 41,771,933 $7,034,321,876 +$61,131,133 $168.85 915
2025 Q4 41,050,745 $6,927,584,838 +$1,487,276,283 $168.77 954
2025 Q3 32,006,624 $4,625,710,203 -$68,198,327 $144.37 796
2025 Q2 31,072,085 $3,936,382,892 +$47,323,412 $126.51 788
2025 Q1 31,036,041 $3,974,324,671 -$396,178,767 $127.90 825
2024 Q4 34,655,995 $4,589,497,492 +$21,795,363 $132.21 868
2024 Q3 35,367,562 $5,150,797,550 -$573,304,257 $145.60 882
2024 Q2 38,432,409 $5,277,616,107 +$719,237 $137.26 886
2024 Q1 38,635,448 $5,300,104,214 +$342,697,016 $137.22 889
2023 Q4 35,699,522 $4,849,731,034 -$440,817,654 $135.85 866
2023 Q3 38,516,647 $4,710,098,168 -$206,156,929 $122.29 828
2023 Q2 40,247,966 $5,110,298,381 -$166,074,410 $126.96 834
2023 Q1 41,326,279 $5,337,459,250 -$427,530,397 $129.16 858
2022 Q4 43,459,538 $5,705,949,548 +$647,747,421 $131.29 895
2022 Q3 39,025,913 $4,565,910,057 -$61,899,980 $116.96 818
2022 Q2 39,837,799 $4,687,241,888 -$150,124,982 $117.63 847
2022 Q1 41,398,739 $5,397,605,243 -$45,866,179 $130.30 880
2021 Q4 41,655,838 $6,352,062,969 -$354,862,874 $152.62 951
2021 Q3 43,883,136 $7,094,482,334 -$474,313,991 $161.68 847
2021 Q2 46,764,551 $7,652,437,559 -$736,351,962 $163.65 853
2021 Q1 50,916,680 $7,666,252,840 -$1,332,296,824 $150.56 833
2020 Q4 58,699,842 $8,895,917,161 +$1,047,035,345 $151.49 844
2020 Q3 54,509,238 $7,377,985,252 -$448,424,368 $135.41 775
2020 Q2 57,604,943 $7,875,097,725 +$1,185,874,028 $136.69 758
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .